Dr. Matthew Galsky:The CheckMate 274 study meticulously explored disease-free survival (DFS) as its cornerstone, encompassing a broad spectrum of patients and highlighting the nuanced benefits in those with high PD-L1 expression. While overall survival (OS) emerges as a critical secondary endpoint, ...
Dr. Matthew Galsky:The CheckMate 274 study meticulously explored disease-free survival (DFS) as its cornerstone, encompassing a broad spectrum of patients and highlighting the nuanced benefits in those with high PD-L1 expression. While overall survival (OS) emerges as a critical secondary endpoint, ...
In addition, we report interim overall survival (OS) data for the first time and an exploratory analysis among patients with bladder primary tumors (muscle-invasive bladder cancer [MIBC]). Consistent DFS benefit with nivolumab versus placebo was observed in both the ITT (hazard ratio [HR], ...
Key secondary endpoints include overall survival (OS) and incidence of adverse events (AEs). Part B of the study is ongoing. About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common ...
survival (PFS) and objective response rates (ORR) in patients treated withOpdivoplus CABOMETYXover sunitinib, regardless of risk classification based on International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scores. Superior overall survival (OS) was also observed in pati...
这些药物的出现,为患者带来了希望的曙光,但它们带来的中位总生存期(Overall Survival,OS)改善相对有限,大约在12个月到14个月之间,而且不良反应(adverse events)的发生率也比较高,患者的耐受性(tolerability)仍有待提高。 近五年来,随着免疫治疗(immunotherapy)的飞速发展,特别是PD-1/PD-L1抑制剂(PD-1/PD-L1 ...
Phase 2 CheckMate 069 Study Suggests Nivolumab Plus Ipilimumab May Improve Overall Survival in MelanomaJonathan GoodmanMPhilOncology Editor
An integrated, comprehensive partitioned survival analysis describes how patients spend overall survival (OS) time, on/off treatment, with/without toxicity. Previous analysis of first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) for aRCC in CheckMate 214 showed treatment-free survival (TFS) ...
P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC)doi:10.1016/j.jtho.2018.08.856L. SchwartzbergB. KorytowskyJ. PenrodY. YuanG. SelvaggiJournal of Thoracic Oncology...
Background Nivolumab (NIVO) + ipilimumab (IPI) combination demonstrated improved overall survival (OS) benefits vs chemotherapy as first-line treatment for advanced NSCLC in both tumor programmed death ligand 1 (PD-L1) expression ≥ 1% and < 1% in CheckMate 227. CheckMate 817 is a multi-cohort...